Introduction
The HIV epidemic continues to expand rapidly in many parts of the world and more than three million new infections are estimated to have occurred during 1995, over 95% of them in developing countries. Sub-Saharan Africa continues to be the most severely affected region, but rapid increases are also being recorded in many parts of southern Asia.' Heterosexual transmission predominates in these regions, and has been estimated to account for more than 90% of adult infections in Africa.2 To date, population based control programmes have focused primarily on behavioural interventions intended to reduce sexual transmission but achieving rapid, substantial, and sustained changes in sexual behaviour is difficult. The World Health Organisation (WHO) has advocated complementing behavioural interventions with improved treatment services for the classic sexually transmitted diseases (STDs) such as gonorrhoea, syphilis, chancroid, and chlamydia. The sexual transmission of HIV is thought to be enhanced in the presence of such STDs, 3 4 which are highly prevalent in many parts of the developing world due at least partly to inadequate treatment services.5 It has been suggested that the treatment of bacterial STDs may be one of the most cost effective health interventions available in some developing countries.67
Well designed randomised trials are recognised as the gold standard for the evaluation of public health interventions, and it is important that such trials are conducted to provide reliable data on the efficacy and cost effectiveness of control strategies, in order to provide a sound basis for health policy and resource allocation. No Investigators from these three trials met at Johns Hopkins University, Baltimore, United States in May 1996 in a joint technical workshop. The purpose of this report is to summarise the consensus of the workshop, with the aim of providing useful input to research on HIV intervention strategies. The report summarises key issues and conclusions concerning (i) the role of community randomised trials; (ii) strategies for STD management; (iii) epidemiological and statistical issues in the design and analysis of community randomised trials; (iv) diagnostic methods for STDs in population surveys; (v) treatment regimens for STDs in rural Africa; and (vi) ethical issues in community trials.
The role of community randomised trials STD control for HIV prevention is an unusual epidemiological strategy in which control of one set of diseases is used to reduce the incidence of another. In all three African trials, the impact of this strategy is being measured directly by randomising entire communities either to an STD intervention arm or to a comparison arm. The main reasons for adopting community randomisation are as follows. Research on innovative approaches, such as "women')s centres" situated in red light districts, is urgently needed. In rural areas, however, high risk groups are generally difficult to define and identify. For this reason, the three African trials have all adopted strategies aimed at the general population.
STD CONTROL THROUGH MASS TREATMENT
Mass treatment involves the treatment of the entire sexually active population, ideally over a large area and within a short period of time. The objective is to achieve an immediate reduction in the prevalence (and hence incidence) of STDs to a low level. It can be applied on one occasion or periodically, depending on the rate at which STDs are reintroduced. The Rakai trial is investigating the impact of repeated inass treatment at approximately 9 monthly intervals.
In principle, mass treatment addresses all the main limitations of other strategies (Fig  1 C) . Asymptomatic infections are treated, infected partners are covered without the need for contact tracing, treatment seeking behaviour is not required, and compliance and treatment effectiveness can be assured through the use of a directly observed single dose oral regimen of proved efficacy. Mass treatment is unlikely to be cheap, but may be highly cost effective if the impact on HIV and other STDs is substantial.
The approach is novel, controversial, and may not always be politically acceptable. There are also concerns about logistics, side effects, and the possible development of drug resistance. Nevertheless, the potential impact of this strategy on morbidity and mortality is so great that it should be evaluated in rigorously designed studies, including careful monitoring for adverse effects. Consideration should be given to evaluating a combined intervention, in which treatment services are improved and a single round of mass treatment is added to bring about an initial reduction in STD prevalence.
Epidemiological and statistical issues
The design of community randomised trials of STD interventions requires careful consideration of sample size (number of units of randomisation and number of individuals within each unit), of methods to ensure comparability between study arms and to adjust for potential confounders, and of analyses to link any impact on HIV to effects on STDs.
SAMPLE SIZE
In all three of the east African trials, interventions were randomly allocated to entire communities rather than to individuals, since the aim was to measure the impact of intervening in a whole population.'9 Standard sample size formulas for individually randomised trials20 have to be amended to take account of the additional random error resulting from between community variability.
An approximate estimate of n, the number of communities required in each arm of the trial, may be obtained as'9:
(1) where X0 and X, are the average incidence rates in the study communities in the absence and presence of the intervention, y is the person years of observation in each community, k is the coefficient of variation (SD/mean) of the (true) incidence rates among the communities in each arm, and f = 10X51 or 7.85 for 90% or 80% power, respectively.
The key quantity in this computation is k, which measures the degree of between community variation. Unfortunately, prior data on k are seldom available, since this would require prospective studies of incidence in the study population before the design is finalised, and these are likely to be too costly and time consuming. In the Mwanza and Masaka trials, the proposal was based on a plausible estimate of k (025), implying that HIV incidence rates in each arm varied roughly between X. ± 2k2&, or from 0.5X. to 1.5&. Smaller values of k may be attained if the communities are large and chosen to be homogeneous, as in the Rakai study.
If prior data are available on HIV prevalence by community, a further option would be to assume that the coefficient of variation of prevalence is similar to that of incidence, and analysis of data from the east African studies is now in progress to evaluate this assumption. Preliminary data from Rakai suggest a k of 0-16 based on baseline HIV prevalence.
SIZE AND DEFINITION OF COMMUNITIES
On purely statistical grounds, a large number of small clusters is preferred to a small number of large clusters, since this reduces the design effect resulting from between community variation and increases power for a given total sample size. An absolute minimum of four or five communities are required per arm, to provide sufficient replication to reach useful conclusions. However, there are two reasons for preferring large communities to small communities. Firstly, this may reduce the level of contamination bias resulting from contact of the study population with other untreated communities, which could dilute the observed impact. Secondly, between community variability (k) may be reduced when larger clusters (XO X1)2 are used, and data from the east African studies will be analysed to assess this. In the Mwanza trial, study communities were relatively large (average population around 25 000) and widely separated, so that travel between communities was time consuming. The study cohort consisted of 1000 people sampled from an "inner zone" within 90 minutes' walk of a central health unit, in order to reduce contamination. In Masaka, the randomisation unit was a "parish", with a population of about 2800. The study cohort was chosen from the three to five villages closest to the health centre, again to reduce contamination. In Rakai, small villages were grouped into "super clusters" (average population around 1200), which were carefully chosen on the basis of social and sexual network studies, so that most sexual contacts were expected to occur within super clusters. Wherever possible, natural barriers such as swamps, hills, and forests were used to provide "buffer zones" between neighbouring super clusters.
MATCHING AND STRATIFICATION
With relatively few units of randomisation, there is a high probability of some imbalances between the trial arms which may influence the results. To minimise this problem, all three trials employed forms of community matching. For example, in the Mwanza trial, six pairs of communities were formed, matched on type of community (roadside, island, rural) and geographical location, and one community in each pair was randomly allocated to the intervention. In Masaka, six matched triplets of parishes were allocated to the three treatment arms. In Rakai, the 10 study communities were grouped into three strata on the basis of projected HIV prevalence, and randomisation performed within strata.
Matching is only effective if the matching factors are closely correlated with the primary endpoint. In the HIV trials, matching on earlier HIV incidence would be the approach of choice, but this was not feasible. Instead, communities were matched on the basis of factors known from previous studies in the areas to be correlated with HIV prevalence. Baseline data from the Mwanza and Masaka trials21 22 confirmed that the matching was highly effective in reducing between community variation in HIV prevalance and thus increasing study power. In Mwanza, the coefficient of variation k in HIV prevalence was 0 49 over all 12 communities, but only 0.28 when computed within pairs. In Masaka, a k of 0.30 was reduced to 0.19 when analysed within matched triplets (data from first 12 parishes). The power of these studies was increased considerably by the matched designs. Matching was of less importance in the Rakai trial, where selection of more homogeneous communities gave a lower value of k at baseline (0.16).
ANALYSIS OF COMMUNITY RANDOMISED TRIALS
A community randomised design requires an appropriate analysis that takes account of between community variation. Methodology for such trials is still under development, but a number of approaches have been reviewed and compared.23 25 Two approaches are available that appear robust to small numbers of clusters, and which also have the advantage of simplicity. These involve computing an overall incidence (or prevalence) rate for each community, and analysing these community level outcomes using the t test24 (after log transformation if appropriate) or randomisation test.25 These methods may be modified to provide confidence intervals as well as significance tests. At least six pairs of communities are required to allow significance at p < 0.05 on a two sided randomisation test, or four or five communities per arm with an unmatched or stratified design. The published report of the Mwanza trial used the paired t test.8
ADJUSTMENT FOR CONFOUNDERS
Because of the small number of randomisation units, imbalances between treatment groups are more likely in community randomised trials than in standard clinical trials. It is therefore important to identify potential confounding factors, both at the individual and community level, and to adjust for them in the analysis. The robust methods of analysis discussed above may be modified to adjust for confounders. 25 In the Mwanza trial,8 for example, a logistic regression model was fitted using data on individuals, and including terms for the matched pair, age group, and each of the identified confounding factors. Observed and expected values from the regression model were used to compute an adjusted rate ratio (RR) of HIV seroconversion for each pair, and the log(RR) were analysed using the paired t test as before.
Criteria for selection of confounders for adjustment have been widely discussed,26 27 and a number of alternative strategies have been recommended. In the Mwanza trial, potential confounders were defined as factors known from previous studies in the area to be correlated with HIV prevalence, and which showed a substantial difference between treatment groups in the baseline survey.21 Analytical plans were prepared before the end of the trial, listing the factors that would be adjusted for in the final analysis. In HIV intervention trials, a factor that may be of particular importance as a potential confounder is the community HIV prevalence at baseline, because it is likely to be correlated with HIV incidence. It is recommended that future trials adjust for baseline prevalence regardless of the degree of imbalance, preferably by means of regression adjustment. In Mwanza, this resulted in modification of the adjusted efficacy from 42% to 38%.28
LINKING HIV IMPACT TO STD EFFECTS
To establish the plausibility of any impact of STD treatment on HIV incidence, it is important to demonstrate that the intervention reduced the incidence and prevalence of target STDs. Analysis of the Mwanza data, with adjustment for baseline prevalences, show a substantial impact on active syphilis in both sexes, and on symptomatic urethritis in males. ' Wet mount and saline preparation for trichomonas diagnosis require immediate microscopic examination, and sensitivity is suboptimal." The Rakai project conducts trichomonas culture using the TV InPouch kit (BioMed Diagnostics, San Jose, CA, USA),34 35 which is inoculated in the field and subsequently read in a field laboratory. Although the cost (approximately US$2) is higher than for wet mount, advantages of the kit include ease of use, high sensitivity and specificity,35 36 and feasibility of home based specimen collection (see below).
Candida albicans can be diagnosed by wet mount, but microscopic examination may miss up to half of culture positive symptomatic candidiasis. 37 Urine specimens Given the limited feasibility of genital examination in household surveys, there are advantages to non-invasive specimen collection by study participants. In the Rakai project, over 94% of male and female participants agreed to provide a urine specimen, collected in the home at the time of interview.
The urinary dipstick leucocyte esterase test (LET), is used to diagnose male urethritis based on esterase produced by polymorphonuclear leucocytes. In the United States, this test has high specificity but low sensitivity.46 In Mwanza, there is a high rate of false positive LET results, possibly due to the high prevalence of Schistosoma haematobium in the region. '0 47 The utility of LET as a survey tool is thus contingent on the rates of gonorrhoea, chlamydia, and other urinary tract pathogens in the population.
In the Rakai project, urine specimens from both males and females are tested by the ligase chain reaction (LCR, Abbott Laboratories, Abbott Park, IL, USA) for gonorrhoea and chlamydia. These tests have high sensitivity and specificity when evaluated against culture.48-51 LCR is currently expensive and requires specialised technology, but specimens can be collected in the home, processed in a small field laboratory, frozen, stored for long periods of time, and shipped to a reference laboratory for analysis. In low prevalence populations, it may be possible to reduce costs through pooling of specimens.
Sely administered vaginal swabs
In Rakai, 95% of women have agreed to and correctly provided two self administered vaginal swabs collected in the home at the time of interview. In the home, one swab is immediately inoculated into the TV InPouch culture kit, and used to assess trichomonas prevalence.34'5 The second swab is used to prepare an air dried slide, which is subsequently Gram stained and scored for bacterial vaginosis. '8 In conclusion, self administered specimen collection has major advantages in terms of population acceptability. Gonorrhoea, chlamydia, trichomonas, and BV can be diagnosed through urine and vaginal swabs collected by the participant in the home. By combining serological specimens with urine and self administered vaginal swabs, the Rakai project has been able to collect reliable data on population rates of most key STDs. Disadvantages of this methodology include cost (LCR is expensive and many uninfected people are screened), and delays in receiving some results (LCR samples are sent to a reference laboratory in the United States for testing). These disadvantages are offset by an ability to assess more reliably the effects of community based interventions and, in the future, to monitor ongoing programmes through sample surveys. The following syndromic approaches were used in the Mwanza trial.
Genital ulcer syndrome (GUS)
The most frequent bacterial causes of GUS are chancroid and syphilis. To cover these diseases, the first line regimen was trimethoprimsulphamethoxazole 320 mg/1600 mg twice daily for 2 days for chancroid and benzathine penicillin 2-4 million units intramuscularly for syphilis. If the ulcer persisted for 7 days, second line treatment was trimethoprimsulphamethoxazole 320 mg/1600 mg twice daily on alternate days x 3, and persistent treatment failures after a further 7 The following algorithms based on the appearance of the discharge were used in Mwanza:
(i) Appears like thrush (that is, Candida):
(ii) Does not appear like thrush: assume discharge due to gonorrhoea, chlamydia, trichomonas, or bacterial vaginosis and treat with first line trimethoprim-sulphamethoxazole 400 mg/2000 mg twice daily for 2 days plus doxycycline 100 mg twice daily for 7 days plus metronidazole 2 g immediately. If discharge persists for 7 days, the second line treatment was doxycycline 100 mg twice daily for 7 days, and if still unresolved, ciprofloxacin 500 mg immediately.
Urethral discharge Men complaining of urethral discharge were treated presumptively for gonorrhoea and chlamydia. First line treatment was trimethoprim-sulphamethoxazole 400 mg/2000 mg twice daily for 2 days plus doxycycline 100 mg twice daily for 7 days. Second line treatment was metronidazole 2 g immediately plus doxycycline 100 mg twice daily for 7 days, and third line treatment ciprofloxacin 500 mg immediately.
Pelvic inflammatory disease (PID) Suspected PID (based on a complaint of lower abdominal pain) was treated presumptively for gonorrhoea, chlamydia, and anaerobic infections. The first line treatment was trimethoprim-sulphamethoxazole 400 mg/2000 mg twice daily for 2 days plus doxycycline 100 mg twice daily for 14 days plus metronidazole 400 mg twice daily for 7 days. Second line treatment was ciprofloxacin 500 mg immediately.
Treatment algorithms in Masaka are broadly similar, the main differences being use of chloramphenicol in place of trimethoprim-sulphamethoxazole for genital discharge and PID, and erythromycin for second line treatment of genital ulcers.
MASS TREATMENT IN THE RAKAI TRIAL
The mass treatment regimen of the Rakai trial combines single oral doses of azithromycin (1 g) and ciprofloxacin (250 mg). Each drug alone is highly effective against gonorrhoea and chancroid54-57; the combined regimen reduces the risk of drug resistance and directly observed therapy ensures compliance. Azithromycin is also highly effective against chlamydia.5558 Ongoing monitoring has revealed no gonorrhoea resistance to azithromycin or ciprofloxacin in samples from people with genital discharge attending Rakai clinical facilities. Under 10% of subjects in the mass treatment arm report side effects, mainly mild gastrointestinal upset which resolves within 2 days. The cost of this drug combination has fallen substantially over the past 2 years. In pregnant women, ciprofloxacin is replaced by cefixime, 400 mg immediately, which is also highly effective against gonorrhoea. 59 A single dose of metronidazole (2 g) is given 1 day later for mass treatment of trichomonas and bacterial vaginosis. This regimen shows high cure rates (over 85%) for trichomonas, an efficacy of over 70% one month after treatment for bacterial vaginosis,"2 and has been shown to be safe during pregnancy.60 In Rakai, this dose was associated with a reduced proportion of women with severe bacterial vaginosis in the intervention arm compared with the control arm 9 months after treatment. 29 However, bacterial vaginosis tends to recur, as has been found by other researchers following both single and multidose treatments. 61 There is no established single dose oral treatment for syphilis, so intramuscular benzathine penicillin (2-4 million units) is given to all intervention arm subjects with serological evidence of syphilis (based on a TRUST test run in the field laboratory). Penicillin is provided in the home within 24 hours after serological testing. Some observations suggest that azithromycin may also be effective against syphilis,62 but the available data refer to a 10 day course and shorter regimens remain to be evaluated.
DRUG RESISTANCE
All STD treatment strategies entail the potential of selecting for bacterial strains with antibiotic resistance. This is of particular concern with multidose treatment regimens and with mass treatment, and for this reason the Rakai trial has used single dose, directly observed treatment and multidrug combinations. The development of resistance may be more difficult to control in the context of routine services, where periodic shortages of drug supplies, or use of drugs of subobtimal quality, may give rise to partial treatment.
Single dose ciprofloxacin is often a component of STD treatment regimens, and while this is unlikely to promote resistance in target organisms such as Neisseria gonorrhoeae,6' there is a possibility of promoting resistance in non-target organisms such as Escherichia coli, Salmonella, and Shigella species. 
